Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves biopharmaceutical companies; biotechnology, agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic, and consumer product companies; contract research and contract manufacturing organizations; other commercial entities; and hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone781-222-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.27 billion
Profitability
Miscellaneous
Employees14,700
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Charles River Laboratories Intl. (NYSE:CRL) Frequently Asked Questions
What is Charles River Laboratories Intl.'s stock symbol?
Charles River Laboratories Intl. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."
How will Charles River Laboratories Intl.'s stock buyback program work?
Charles River Laboratories Intl. declared that its board has approved a stock buyback plan on Sunday, June 4th 2017, which authorizes the company to buyback $150,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company's management believes its shares are undervalued.
How were Charles River Laboratories Intl.'s earnings last quarter?
Charles River Laboratories Intl. Inc (NYSE:CRL) announced its earnings results on Wednesday, February, 13th. The medical research company reported $1.49 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.39 by $0.10. The medical research company had revenue of $605.53 million for the quarter, compared to analyst estimates of $589.86 million. Charles River Laboratories Intl. had a return on equity of 24.09% and a net margin of 9.99%. The company's quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.40 earnings per share. View Charles River Laboratories Intl.'s Earnings History.
When is Charles River Laboratories Intl.'s next earnings date?
What guidance has Charles River Laboratories Intl. issued on next quarter's earnings?
Charles River Laboratories Intl. updated its FY 2019 earnings guidance on Wednesday, February, 13th. The company provided earnings per share (EPS) guidance of $6.25-6.40 for the period, compared to the Thomson Reuters consensus estimate of $6.35. The company issued revenue guidance of $2.504-2.538 billion, compared to the consensus revenue estimate of $2.49 billion.
What price target have analysts set for CRL?
14 brokerages have issued twelve-month price targets for Charles River Laboratories Intl.'s shares. Their forecasts range from $115.00 to $162.00. On average, they anticipate Charles River Laboratories Intl.'s stock price to reach $141.3846 in the next year. This suggests that the stock has a possible downside of 0.7%. View Analyst Price Targets for Charles River Laboratories Intl..
What is the consensus analysts' recommendation for Charles River Laboratories Intl.?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories Intl. in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Charles River Laboratories Intl..
Has Charles River Laboratories Intl. been receiving favorable news coverage?
Media stories about CRL stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Charles River Laboratories Intl. earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Charles River Laboratories Intl.'s key competitors?
Some companies that are related to Charles River Laboratories Intl. include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL) and Luna Innovations (LUNA).
What other stocks do shareholders of Charles River Laboratories Intl. own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories Intl. investors own include Celgene (CELG), Intel (INTC), Pfizer (PFE), Johnson & Johnson (JNJ), Boeing (BA), Merck & Co., Inc. (MRK), Emerson Electric (EMR), Vereit (VER), AbbVie (ABBV) and Esperion Therapeutics (ESPR).
Who are Charles River Laboratories Intl.'s key executives?
Charles River Laboratories Intl.'s management team includes the folowing people:
- Mr. James C. Foster, Chairman, CEO & Pres (Age 68)
- Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 53)
- Mr. David P. Johst, Corp. Exec. VP, HR, Gen. Counsel & Chief Admin. Officer (Age 57)
- Mr. William D. Barbo, Chief Commercial Officer & Corp. Exec. VP (Age 58)
- Mr. Michael Gunnar Knell, Corp. Sr. VP & Chief Accounting Officer (Age 42)
Who are Charles River Laboratories Intl.'s major shareholders?
Charles River Laboratories Intl.'s stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.42%), FMR LLC (3.75%), First Trust Advisors LP (2.29%), Lord Abbett & CO. LLC (1.76%), Brown Advisory Inc. (1.66%) and Congress Asset Management Co. MA (1.60%). Company insiders that own Charles River Laboratories Intl. stock include Birgit Girshick, Bradley Nixon Scharfe, C Richard Reese, David P Johst, David Ross Smith, Davide Molho, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, Jason Wesley Scharfe, Joseph W Laplume, Kevin Ma, Online Communications Bdirect, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories Intl..
Which institutional investors are selling Charles River Laboratories Intl. stock?
CRL stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Acadian Asset Management LLC, Channing Capital Management LLC, Victory Capital Management Inc., D. E. Shaw & Co. Inc., Bank of New York Mellon Corp, Copper Rock Capital Partners LLC and Lord Abbett & CO. LLC. Company insiders that have sold Charles River Laboratories Intl. company stock in the last year include Birgit Girshick, David P Johst, David Ross Smith, Davide Molho, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, Joseph W Laplume, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories Intl..
Which institutional investors are buying Charles River Laboratories Intl. stock?
CRL stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Epoch Investment Partners Inc., First Trust Advisors LP, Westfield Capital Management Co. LP, Mackay Shields LLC, Squarepoint Ops LLC, Fisher Asset Management LLC and Bank of Nova Scotia. View Insider Buying and Selling for Charles River Laboratories Intl..
How do I buy shares of Charles River Laboratories Intl.?
Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Charles River Laboratories Intl.'s stock price today?
One share of CRL stock can currently be purchased for approximately $142.35.
How big of a company is Charles River Laboratories Intl.?
Charles River Laboratories Intl. has a market capitalization of $6.87 billion and generates $2.27 billion in revenue each year. The medical research company earns $226.37 million in net income (profit) each year or $6.03 on an earnings per share basis. Charles River Laboratories Intl. employs 14,700 workers across the globe.
What is Charles River Laboratories Intl.'s official website?
How can I contact Charles River Laboratories Intl.?
Charles River Laboratories Intl.'s mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]
MarketBeat Community Rating for Charles River Laboratories Intl. (NYSE CRL)
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories Intl. and other stocks. Vote "Outperform" if you believe CRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
